0001127602-20-008429.txt : 20200228 0001127602-20-008429.hdr.sgml : 20200228 20200228191633 ACCESSION NUMBER: 0001127602-20-008429 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200219 FILED AS OF DATE: 20200228 DATE AS OF CHANGE: 20200228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ACKERMANN CHRISTINA CENTRAL INDEX KEY: 0001681871 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-14956 FILM NUMBER: 20673577 MAIL ADDRESS: STREET 1: 400 SOMERSET CORPORATE BOULEVARD CITY: BRIDGEWATER STATE: NJ ZIP: 08807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Bausch Health Companies Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 BUSINESS PHONE: 514-744-6792 MAIL ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 FORMER COMPANY: FORMER CONFORMED NAME: Valeant Pharmaceuticals International, Inc. DATE OF NAME CHANGE: 20100928 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 4/A 1 form4a.xml PRIMARY DOCUMENT X0306 4/A 2020-02-19 2020-02-21 0000885590 Bausch Health Companies Inc. BHC 0001681871 ACKERMANN CHRISTINA 400 SOMERSET CORPORATE BOULEVARD BRIDGEWATER NJ 08807 1 EVP AND GENERAL COUNSEL Common Shares, No Par Value 2020-02-19 4 M 0 7864 A 55029 D Restricted Share Units 2020-02-19 4 M 0 7864 D Common Stock 7864 0 D Reflects common shares, no par value ("Common Shares") of Bausch Health Companies Inc. (the "Company") issued to the reporting person in connection with the vesting of performance-based Restricted Share Units ("PSUs") granted to the reporting person on January 6, 2017. On January 6, 2017, the reporting person was granted PSUs that were distributed on February 19, 2020 following certification of the achievement of certain performance metrics. This Form 4/A is being filed solely to reflect the acquisition of 7,864 Common Shares instead of the disposition of Common Shares originally reported on the Form 4 filed on February 21, 2020. Each PSU converts into Common Shares on a one-for-one basis. This PSU award was previously reported on a Form 4 filed on January 10, 2017 with the maximum potential award amount of 16,384 shares. Any portion of the award not vested on February 19, 2020 was terminated as of that date. /s/ Kirsten O'Donnell, attorney-in-fact for Christina Ackermann 2020-02-28